GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kabra Drugs Ltd (BOM:524322) » Definitions » EPS (Basic)

Kabra Drugs (BOM:524322) EPS (Basic) : ₹-5.54 (TTM As of Mar. 2025)


View and export this data going back to 1993. Start your Free Trial

What is Kabra Drugs EPS (Basic)?

Kabra Drugs's basic earnings per share (Basic EPS) for the three months ended in Mar. 2025 was ₹0.17. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2025 was ₹-5.54.

Kabra Drugs's EPS (Diluted) for the three months ended in Mar. 2025 was ₹0.17. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was ₹-5.54.

Kabra Drugs's EPS without NRI for the three months ended in Mar. 2025 was ₹0.17. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2025 was -5.54.

During the past 3 years, the average EPS without NRI Growth Rate was -33.10% per year. During the past 5 years, the average EPS without NRI Growth Rate was -52.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Kabra Drugs's highest 3-Year average EPS without NRI Growth Rate was 95.40% per year. The lowest was -78.20% per year. And the median was -10.95% per year.


Kabra Drugs EPS (Basic) Historical Data

The historical data trend for Kabra Drugs's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kabra Drugs EPS (Basic) Chart

Kabra Drugs Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.41 -0.42 -0.77 -1.68 -0.99

Kabra Drugs Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.85 -1.24 -3.94 -0.53 0.17

Kabra Drugs EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Kabra Drugs's Basic EPS for the fiscal year that ended in Mar. 2025 is calculated as

Basic EPS (A: Mar. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-10.856-0)/23.708
=-0.46

Kabra Drugs's Basic EPS for the quarter that ended in Mar. 2025 is calculated as

Basic EPS (Q: Mar. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(3.929-0)/23.708
=0.17

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-5.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kabra Drugs  (BOM:524322) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Kabra Drugs EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Kabra Drugs's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.


Kabra Drugs Business Description

Traded in Other Exchanges
N/A
Address
No. 3, Swaminathan Street, 2nd Floor, West Mambalam, Chennai, TN, IND, 600 033
Kabra Drugs Ltd is an India-based drug manufacturing company. It is engaged in the business of Permaculture manufacturing and trading in pharma related products. Geographically, all the company operations are carried out in India. The company's drug manufacturing plant is located in Madhya Pradesh, India. Its products include Cardiovascular Drugs, Anti-Infective Drugs, Oncology Drugs, Gastroenterologic Drugs, Hormonal Drugs, etc.

Kabra Drugs Headlines

No Headlines